112 related articles for article (PubMed ID: 9486869)
41. Force and stiffness of old dystrophic (mdx) mouse skeletal muscles.
Bobet J; Mooney RF; Gordon T
Muscle Nerve; 1998 Apr; 21(4):536-9. PubMed ID: 9533791
[TBL] [Abstract][Full Text] [Related]
42. Adeno-associated virus-mediated microdystrophin expression protects young mdx muscle from contraction-induced injury.
Liu M; Yue Y; Harper SQ; Grange RW; Chamberlain JS; Duan D
Mol Ther; 2005 Feb; 11(2):245-56. PubMed ID: 15668136
[TBL] [Abstract][Full Text] [Related]
43. Diaphragm tension reduced in dystrophic mice by an oxidant, hypochlorous acid.
Lafoux A; Divet A; Gervier P; Huchet-Cadiou C
Can J Physiol Pharmacol; 2010 Feb; 88(2):130-40. PubMed ID: 20237587
[TBL] [Abstract][Full Text] [Related]
44. Skeletal muscle fibrosis in the mdx/utrn+/- mouse validates its suitability as a murine model of Duchenne muscular dystrophy.
Gutpell KM; Hrinivich WT; Hoffman LM
PLoS One; 2015; 10(1):e0117306. PubMed ID: 25607927
[TBL] [Abstract][Full Text] [Related]
45. Progressive nuclear factor-kappaB activation resistant to inhibition by contraction and curcumin in mdx mice.
Durham WJ; Arbogast S; Gerken E; Li YP; Reid MB
Muscle Nerve; 2006 Sep; 34(3):298-303. PubMed ID: 16718687
[TBL] [Abstract][Full Text] [Related]
46. Susceptibility to sarcomere injury induced by single stretches of maximally activated muscles of mdx mice.
Consolino CM; Brooks SV
J Appl Physiol (1985); 2004 Feb; 96(2):633-8. PubMed ID: 14715682
[TBL] [Abstract][Full Text] [Related]
47. Combined effect of AAV-U7-induced dystrophin exon skipping and soluble activin Type IIB receptor in mdx mice.
Hoogaars WM; Mouisel E; Pasternack A; Hulmi JJ; Relizani K; Schuelke M; Schirwis E; Garcia L; Ritvos O; Ferry A; 't Hoen PA; Amthor H
Hum Gene Ther; 2012 Dec; 23(12):1269-79. PubMed ID: 22894762
[TBL] [Abstract][Full Text] [Related]
48. Evaluation of the therapeutic potential of carbonic anhydrase inhibitors in two animal models of dystrophin deficient muscular dystrophy.
Giacomotto J; Pertl C; Borrel C; Walter MC; Bulst S; Johnsen B; Baillie DL; Lochmüller H; Thirion C; Ségalat L
Hum Mol Genet; 2009 Nov; 18(21):4089-101. PubMed ID: 19648295
[TBL] [Abstract][Full Text] [Related]
49. The mdx mouse diaphragm reproduces the degenerative changes of Duchenne muscular dystrophy.
Stedman HH; Sweeney HL; Shrager JB; Maguire HC; Panettieri RA; Petrof B; Narusawa M; Leferovich JM; Sladky JT; Kelly AM
Nature; 1991 Aug; 352(6335):536-9. PubMed ID: 1865908
[TBL] [Abstract][Full Text] [Related]
50. Urocortins improve dystrophic skeletal muscle structure and function through both PKA- and Epac-dependent pathways.
Reutenauer-Patte J; Boittin FX; Patthey-Vuadens O; Ruegg UT; Dorchies OM
Am J Pathol; 2012 Feb; 180(2):749-62. PubMed ID: 22192627
[TBL] [Abstract][Full Text] [Related]
51. Acute failure of action potential conduction in mdx muscle reveals new mechanism of contraction-induced force loss.
Call JA; Warren GL; Verma M; Lowe DA
J Physiol; 2013 Aug; 591(15):3765-76. PubMed ID: 23753524
[TBL] [Abstract][Full Text] [Related]
52. Dystrophic mdx mice develop severe cardiac and respiratory dysfunction following genetic ablation of the anti-inflammatory cytokine IL-10.
Nitahara-Kasahara Y; Hayashita-Kinoh H; Chiyo T; Nishiyama A; Okada H; Takeda S; Okada T
Hum Mol Genet; 2014 Aug; 23(15):3990-4000. PubMed ID: 24659498
[TBL] [Abstract][Full Text] [Related]
53. Protective effect of female gender-related factors on muscle force-generating capacity and fragility in the dystrophic mdx mouse.
Hourdé C; Joanne P; Noirez P; Agbulut O; Butler-Browne G; Ferry A
Muscle Nerve; 2013 Jul; 48(1):68-75. PubMed ID: 23625771
[TBL] [Abstract][Full Text] [Related]
54. Genetic deletion of muscle RANK or selective inhibition of RANKL is not as effective as full-length OPG-fc in mitigating muscular dystrophy.
Dufresne SS; Boulanger-Piette A; Bossé S; Argaw A; Hamoudi D; Marcadet L; Gamu D; Fajardo VA; Yagita H; Penninger JM; Russell Tupling A; Frenette J
Acta Neuropathol Commun; 2018 Apr; 6(1):31. PubMed ID: 29699580
[TBL] [Abstract][Full Text] [Related]
55. Systemic administration of L-arginine benefits mdx skeletal muscle function.
Barton ER; Morris L; Kawana M; Bish LT; Toursel T
Muscle Nerve; 2005 Dec; 32(6):751-60. PubMed ID: 16116642
[TBL] [Abstract][Full Text] [Related]
56. Adaptive strength gains in dystrophic muscle exposed to repeated bouts of eccentric contraction.
Call JA; Eckhoff MD; Baltgalvis KA; Warren GL; Lowe DA
J Appl Physiol (1985); 2011 Dec; 111(6):1768-77. PubMed ID: 21960659
[TBL] [Abstract][Full Text] [Related]
57. Eicosapentaenoic acid decreases TNF-α and protects dystrophic muscles of mdx mice from degeneration.
Machado RV; Mauricio AF; Taniguti AP; Ferretti R; Neto HS; Marques MJ
J Neuroimmunol; 2011 Mar; 232(1-2):145-50. PubMed ID: 21131061
[TBL] [Abstract][Full Text] [Related]
58. Long-term clenbuterol administration alters the isometric contractile properties of skeletal muscle from normal and dystrophin-deficient mdx mice.
Hayes A; Williams DA
Clin Exp Pharmacol Physiol; 1994 Oct; 21(10):757-65. PubMed ID: 7867226
[TBL] [Abstract][Full Text] [Related]
59. Similar efficacy from specific and non-specific mineralocorticoid receptor antagonist treatment of muscular dystrophy mice.
Lowe J; Floyd KT; Rastogi N; Schultz EJ; Chadwick JA; Swager SA; Zins JG; Kadakia FK; Smart S; Gomez-Sanchez EP; Gomez-Sanchez CE; Raman SV; Janssen PM; Rafael-Fortney JA
J Neuromuscul Dis; 2016; 3(3):395-404. PubMed ID: 27822449
[TBL] [Abstract][Full Text] [Related]
60. Acute pathophysiological effects of muscle-expressed Dp71 transgene on normal and dystrophic mouse muscle.
Wieneke S; Heimann P; Leibovitz S; Nudel U; Jockusch H
J Appl Physiol (1985); 2003 Nov; 95(5):1861-6. PubMed ID: 14555666
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
